BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 28, 2019
View Archived Issues
lncRNA 00607 as a tumor suppressor in hepatocellular carcinoma
Read More
Intrabone gene therapy with autologous HSCs for transfusion-dependent beta-thalassemia: phase I/II
Read More
Collateral undamage: novel arterial growth mechanism underlies neonatal heart regeneration
Read More
Mannin Research and McMaster University enter glaucoma drug collaboration
Read More
NIAID initiates phase I study of the VRC-HIVRGP096-00-VP HIV vaccine
Read More
Myelin can regenerate in MS but mostly doesn't
Read More
Recombination, mutation probabilities linked
Read More
Immunosuppressive peptide R9-SOCS1-KIR prevents ocular damage in models of autoimmune uveitis
Read More
VCN-01 shows promising activity in preclinical models and in phase I study of retinoblastoma
Read More
Novo Nordisk initiates phase I pharmacokinetic study of NNC0148-0287sema in type 2 diabetes
Read More
New phase I trial investigates use of MK-5475 in moderate to severe PAH
Read More
SRPK1 found as therapeutic target for treating acute myeloid leukemia
Read More
I-Mab Biopharma begins first-in-human study of TJ-003234
Read More
Withyou Biotechnology describes new ACE inhibitors
Read More
Destiny Pharma reports data from second phase I safety study of XF-73
Read More
FDA approves Imbruvica with obinutuzumab for treatment-naive CLL/SLL
Read More
Vaccine targeting mucin-1 designed to function in immunotolerant hosts
Read More
Phase III study of Ultomiris in aHUS meets primary objective of complete TMA response
Read More
FDA lifts partial clinical hold on phase I studies of MGD-009
Read More